A potential approach toward the management of sepsis: The extracorporeal cytokine hemadsorption therapy.
Journal
Seminars in dialysis
ISSN: 1525-139X
Titre abrégé: Semin Dial
Pays: United States
ID NLM: 8911629
Informations de publication
Date de publication:
12 Dec 2023
12 Dec 2023
Historique:
revised:
11
11
2023
received:
11
06
2023
accepted:
20
11
2023
medline:
12
12
2023
pubmed:
12
12
2023
entrez:
12
12
2023
Statut:
aheadofprint
Résumé
Infectious diseases are among the most common cause of morbidity and mortality among hospitalized patients while systemic inflammatory response syndrome is primarily attributed to the imbalance between pro-inflammatory and anti-inflammatory cytokines. Despite the improvements in the antibiotherapy alternatives and diagnostic modalities, the morbidity and mortality rates of sepsis and septic shock are relatively high among patients admitted to the intensive care units. Extracorporeal cytokine hemadsorption therapies are therapeutic approaches for such patient group with promising early results that especially have grown during COVID-19 pandemic. In this narrative review, our aim is to evaluate the current pre-clinical and clinical knowledge regarding the use of cytokine filtration systems among patients with septic shock.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517-528. doi:10.1007/s00281-017-0639-8
Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci. 2013;50(1):23-36. doi:10.3109/10408363.2013.764490
Chaudhry H, Zhou J, Zhong Y, et al. Role of cytokines as a double-edged sword in sepsis. In Vivo. 2013;27(6):669-684.
Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11(2):R49. doi:10.1186/cc5783
Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101(10):3765-3777. doi:10.1182/blood-2002-06-1887
Pei G, Zhang Z, Peng J, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J am Soc Nephrol. 2020;31(6):1157-1165. doi:10.1681/ASN.2020030276
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943. doi:10.1001/jamainternmed.2020.0994
Desai TR, Leeper NJ, Hynes KL, Gewertz BL. Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J Surg Res. 2002;104(2):118-123. doi:10.1006/jsre.2002.6415
Li XQ, Liu H, Meng Y, et al. Critical roles of cytokine storm and secondary bacterial infection in acute kidney injury development in COVID-19: a multi-center retrospective cohort study. J Med Virol. 2021;93(12):6641-6652. doi:10.1002/jmv.27234
Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19. Immunity. 2020;53(1):19-25. doi:10.1016/j.immuni.2020.06.017
Alharthy A, Faqihi F, Memish ZA, et al. Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: a case-series. Artif Organs. 2021;45(5):E101-e12. doi:10.1111/aor.13864
Hawchar F, László I, Öveges N, Trásy D, Ondrik Z, Molnar Z. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care. 2019;49:172-178. doi:10.1016/j.jcrc.2018.11.003
Rieder M, Wengenmayer T, Staudacher D, Duerschmied D, Supady A. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation. Crit Care. 2020;24(1):435. doi:10.1186/s13054-020-03130-y
Rampino T, Gregorini M, Perotti L, et al. Hemoperfusion with CytoSorb as adjuvant therapy in critically ill patients with SARS-CoV2 pneumonia. Blood Purif. 2021;50(4-5):566-571. doi:10.1159/000511725
Berlot G, Pintacuda S, Moro E, et al. Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: preliminary results. Int J Artif Organs. 2022;45(1):75-80. doi:10.1177/0391398821989334
Lebreton G, Dorgham K, Quentric P, Combes A, Gorochov G, Schmidt M. Longitudinal cytokine profiling in patients with severe COVID-19 on extracorporeal membrane oxygenation and Hemoadsorption. Am J Respir Crit Care Med. 2021;203(11):1433-1435. doi:10.1164/rccm.202011-4140LE
Zuccari S, Damiani E, Domizi R, et al. Changes in cytokines, Haemodynamics and microcirculation in patients with sepsis/septic shock undergoing continuous renal replacement therapy and blood purification with CytoSorb. Blood Purif. 2020;49(1-2):107-113. doi:10.1159/000502540
Kogelmann K, Scheller M, Drüner M, Jarczak D. Use of hemoadsorption in sepsis-associated ECMO-dependent severe ARDS: a case series. J Intensive Care Soc. 2020;21(2):183-190. doi:10.1177/1751143718818992
Rugg C, Klose R, Hornung R, et al. Hemoadsorption with CytoSorb in septic shock reduces catecholamine requirements and in-hospital mortality: a single-center retrospective 'Genetic' matched analysis. Biomedicine. 2020;8(12):539. doi:10.3390/biomedicines8120539
Brouwer WP, Duran S, Kuijper M, Ince C. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care. 2019;23(1):317. doi:10.1186/s13054-019-2588-1
Geraci TC, Kon ZN, Moazami N, et al. Hemoadsorption for management of patients on veno-venous ECMO support for severe COVID-19 acute respiratory distress syndrome. J Card Surg. 2021;36(11):4256-4264. doi:10.1111/jocs.15785
Pieri M, Fominskiy E, Nardelli P, Bonizzoni MA, Scandroglio AM. CytoSorb purification in critically ill SARS-CoV-2 patients. Int J Artif Organs. 2022;45(2):216-220. doi:10.1177/03913988211052572
Rieder M, Duerschmied D, Zahn T, et al. Cytokine adsorption in severe acute respiratory failure requiring Veno-venous extracorporeal membrane oxygenation. ASAIO j. 2021;67(3):332-338. doi:10.1097/MAT.0000000000001302
Stockmann H, Thelen P, Stroben F, et al. CytoSorb rescue for COVID-19 patients with Vasoplegic shock and multiple organ failure: a prospective, open-label, randomized controlled pilot study. Crit Care Med. 2022;50(6):964-976. doi:10.1097/CCM.0000000000005493
Hawchar F, Tomescu D, Träger K, et al. Hemoadsorption in the critically ill-final results of the international CytoSorb registry. PLoS ONE. 2022;17(10):e0274315. doi:10.1371/journal.pone.0274315
Akil A, Napp LC, Rao C, Klaus T, Scheier J, Pappalardo F. Use of CytoSorb© Hemoadsorption in patients on Veno-venous ECMO support for severe acute respiratory distress syndrome: a systematic review. J Clin Med. 2022;11(20):5990. doi:10.3390/jcm11205990
Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol. 2013;25(4):477-483. doi:10.1016/j.coi.2013.05.006
Monneret G, Finck ME, Venet F, et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett. 2004;95(2):193-198. doi:10.1016/j.imlet.2004.07.009
van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17(7):407-420. doi:10.1038/nri.2017.36
Schädler D, Pausch C, Heise D, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS ONE. 2017;12(10):e0187015. doi:10.1371/journal.pone.0187015
Friesecke S, Träger K, Schittek GA, et al. International registry on the use of the CytoSorb® adsorber in ICU patients : study protocol and preliminary results. Med Klin Intensivmed Notfmed. 2019;114(8):699-707. doi:10.1007/s00063-017-0342-5
Peng ZY, Wang HZ, Carter MJ, et al. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int. 2012;81(4):363-369. doi:10.1038/ki.2011.320
Javanbakht M, Trevor M, Rezaei Hemami M, et al. Ticagrelor removal by CytoSorb(®) in patients requiring emergent or urgent cardiac surgery: a UK-based cost-utility analysis. Pharmacoecon Open. 2020;4(2):307-319. doi:10.1007/s41669-019-00183-w